Pfizer (NYSE:PFE) Stock Rating Reaffirmed by Credit Suisse Group
Credit Suisse Group reaffirmed their neutral rating on shares of Pfizer (NYSE:PFE) in a report released on Monday morning, AnalystRatings.com reports.
Several other research analysts also recently issued reports on PFE. UBS Group reaffirmed a neutral rating and set a $43.00 price objective on shares of Pfizer in a report on Monday, August 5th. Goldman Sachs Group reaffirmed a buy rating and set a $49.00 price objective on shares of Pfizer in a report on Monday, June 17th. JPMorgan Chase & Co. set a $46.00 price objective on Pfizer and gave the stock a neutral rating in a report on Monday, July 29th. Bank of America downgraded Pfizer from a buy rating to a neutral rating in a report on Tuesday, July 30th. Finally, Barclays reaffirmed a hold rating and set a $41.00 price objective on shares of Pfizer in a report on Thursday, May 9th. Fourteen analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock currently has a consensus rating of Hold and an average target price of $46.56.
NYSE:PFE opened at $34.48 on Monday. The stock’s fifty day moving average price is $41.01 and its two-hundred day moving average price is $41.72. Pfizer has a 52-week low of $33.97 and a 52-week high of $46.47. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.27 and a current ratio of 1.47. The company has a market cap of $194.69 billion, a price-to-earnings ratio of 11.49, a P/E/G ratio of 2.81 and a beta of 0.63.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, August 2nd will be paid a $0.36 dividend. This represents a $1.44 dividend on an annualized basis and a dividend yield of 4.18%. The ex-dividend date is Thursday, August 1st. Pfizer’s dividend payout ratio (DPR) is currently 48.00%.
In other news, EVP Frank A. Damelio sold 153,184 shares of the stock in a transaction on Tuesday, July 2nd. The stock was sold at an average price of $44.09, for a total value of $6,753,882.56. Following the transaction, the executive vice president now owns 489,647 shares of the company’s stock, valued at approximately $21,588,536.23. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Alexander R. Mackenzie sold 30,000 shares of the stock in a transaction on Thursday, June 20th. The shares were sold at an average price of $44.00, for a total value of $1,320,000.00. Following the completion of the transaction, the insider now directly owns 80,094 shares in the company, valued at approximately $3,524,136. The disclosure for this sale can be found here. Corporate insiders own 0.09% of the company’s stock.
A number of institutional investors have recently modified their holdings of the stock. Evolution Wealth Advisors LLC bought a new position in Pfizer during the 2nd quarter worth about $34,000. IMA Wealth Inc. increased its holdings in Pfizer by 144.5% during the 2nd quarter. IMA Wealth Inc. now owns 807 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 477 shares in the last quarter. Winch Advisory Services LLC increased its holdings in Pfizer by 69.6% during the 4th quarter. Winch Advisory Services LLC now owns 819 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 336 shares in the last quarter. Ruggie Capital Group bought a new position in Pfizer during the 4th quarter worth about $44,000. Finally, Financial Gravity Wealth Inc. increased its holdings in Pfizer by 33.2% during the 2nd quarter. Financial Gravity Wealth Inc. now owns 1,031 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 257 shares in the last quarter. 71.81% of the stock is currently owned by institutional investors and hedge funds.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Read More: New Google Finance Tool and Screening Stocks
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.